i know it seems crazy but the data didn't come out. the delay could be for any number of reasons including it being so good that the FDA approves the drug ! Mid stage data was really good; so one has to wonder if there is bad news at all. Looks like an opportunity risk/reward balanced with stock already down 17% today.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.